Product Code: GVR-4-68038-561-8
COVID-19 Diagnostics Market Growth & Trends:
The global COVID-19 diagnostics market size is expected to reach USD 50.1 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 7.7% from 2022 to 2030. Since testing is pivotal for effective management of the rising burden of coronavirus cases, the rate at which testing is performed has witnessed a steep increase. More than 150 million tests have been performed in the U.S. as of November 2020, followed by more than 100 million tests conducted in India, and around 20 million tests performed in Brazil.
A paradigm shift towards Point-of-Care (PoC) COVID-19 testing is estimated to offer significant momentum to the market expansion in the near future. Point-of-care (POC) testing enables accurate real-time, lab-quality diagnostic results at patient care settings, such as urgent care centers, hospitals, clinics, and emergency rooms. In response to the pandemic, many diagnostic test manufacturers are focused on the development of rapid and easy-to-use POC COVID-19 diagnostic tests to facilitate testing outside of laboratory settings.
High investments by medical technology companies are expected to offer profitable opportunities for the coronavirus testing industry. These companies have witnessed a moderate to high spike in the revenue generated by the diagnostics/testing business segments in 2020, attributed to the pandemic outbreak. Such key industry entities have also witnessed a high influx of orders exceeding their manufacturing capacities, which has compelled these companies to increase their output by reorganizing their test production structures.
After many fast diagnostic kits failed to detect the presence of the COVID-19 virus in most patients across countries, molecular-based PCR testing for COVID-19 called Real-Time Reverse Transcription Polymer Chain Reaction was developed. WHO named the RT-PCR the standard test for COVID-19 diagnosis, and the number of molecular diagnostic test manufacturers has increased drastically. This trend is being observed in several established, emerging, and developing countries, resulting in a strong need for molecular diagnostic testing. These tests are carried out on those who have had the most exposure to the covid-19 virus, including healthcare workers and medical practitioners.
Expanding scales of COVID-19 testing are expected to be a boon for various medical technology companies operating in the market. Additionally, the government authorities are actively moving forward to scale up COVID-19 testing, further creating a favorable environment for emerging diagnostic companies and new entrants. Both smaller entities and multi-national companies have undertaken unprecedented mobilization to ensure the timely availability of the tests.
Companies such as F. Hoffman-La Roche Ltd.; Thermo Fisher Scientific, Inc.; Perkin Elmer, Inc.; Laboratory Corporation of America Holdings; and Abbott have marked their presence in the market with highly efficient FDA-approved tests for coronavirus infection. The companies are implementing commercially viable strategies to gain a competitive advantage in the market. These include new test development, collaborations and partnerships with key stakeholders, and business expansion strategies to fulfill the demand of their customers across the globe.
High investments in the development, as well as commercialization of antibody and antigen COVID-19 tests by key industry participants, have been witnessed recently and this trend is expected to gain significant momentum in the coming years. For instance, in October 2020, Roche announced the launch of Elecsys SARS-CoV-2 Antigen test to support high volume COVID-19 testing of suspected patients. The test is anticipated to be available by the end of 2020 in the European market. Similarly, in October 2020, Thermo Fisher Scientific, Inc. launched two antibody tests, namely, OmniPATH COVID-19 Total Antibody ELISA and EliA SARS-CoV-2-Sp1 IgG tests for the screening of antibodies against the virus. This initiative was intended to expand the testing capabilities of the company against COVID-19.
COVID-19 Diagnostics Market Report Highlights:
- By end-use, the diagnostic centers and clinics segment is estimated to witness the fastest growth from 2022 to 2030. This is attributed to the fact that the service providers are boosting their testing capabilities by expanding technological footprints in existing labs and diagnostic centers as well as by launching new, high-capacity laboratories
- Based on sample type, the nasopharyngeal swabs segment accounted for revenue share of 44.0% in 2021. Nasopharyngeal swabs are the most preferred for COVID-19 sample collection. These swabs are employed in PCR-based COVID-19 tests at a large scale, boosting the segment's revenue generation capacity
- The non-POC testing segment held a major market share of over 60.0% in 2021 and is expected to dominate the market during the forecast period. During 2020 and 2021 most COVID-19 tests were performed in laboratories and diagnostics centers, making centralized or laboratory testing the most common testing modality on the market. The use of automated high throughput systems allows for the efficient processing of many samples in a short amount of time while maintaining the quality and integrity of the final product
- In terms of mode, the PoC segment is expected to witness the fastest growth from 2022 to 2030. Increasing popularity of at-home testing and handheld instruments targeted toward combating the shortage of coronavirus test kits has been witnessed. This has propelled the adoption of PoC COVID-19 tests
- The laboratories end-use segment accounted for the largest revenue share of 39.6% in 2021. An increasing number of laboratories are leveraging high-throughput technologies to process COVID-19 tests rapidly and effectively on a large scale. This is driven by the effective implementation of favorable reimbursement policies in developed economies
- The Asia Pacific is projected to show the fastest growth during the forecast period from 2022 to 2030. This is attributed to the robust funding for fast-track clinical validation studies with respect to rapid tests for COVID-19 diagnosis, along with minimizing the duration required to introduce novel products. The increasing pool of local diagnostic kits and reagents manufacturers providing testing solutions for COVID-19 detection is anticipated to contribute to revenue generation in the region
- Furthermore, key market players are focusing on increasing research and development and technological advancement to provide efficient diagnostics services and products. For instance, in November 2021, Siemens Healthcare GmbH announced that it has developed an algorithm that predicts life-threatening multiorgan dysfunction and potential progression of the disease. The company named it as Atellica COVID-19 Severity Algorithm
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Research Methodology
- 1.2 Research Assumptions
- 1.2.1 Estimates and Forecast Timeline
- 1.3 Information Procurement
- 1.3.1 Purchased Database
- 1.3.2 GVR's Internal Database
- 1.3.3 Secondary Sources
- 1.3.4 Primary Research
- 1.3.5 Details of Primary Research
- 1.4 Information or Data Analysis
- 1.4.1 Data Analysis Models
- 1.5 Market Formulation & Validation
- 1.6 Model Details
- 1.6.1 Commodity Flow Analysis
- 1.6.1.1 Approach 1: Commodity Flow Approach
- 1.6.2 Volume Price Analysis (Model 2)
- 1.6.2.1 Approach 2: Volume Price Analysis
- 1.6.2.2 revenue modeling
- 1.6.2.3 Workflow mapping of covid-19 diagnostics
- 1.7 List of Secondary Sources
- 1.8 List of Primary Sources
Chapter 2 Executive Summary
- 2.1 COVID-19 Diagnostics Market: Market Outlook
- 2.2 COVID-19 Diagnostics Market: Market Segmentation
- 2.3 COVID-19 Diagnostics Market: Competitive Insights
Chapter 3 Industry Outlook
- 3.1 Parent Market
- 3.2 Penetration & Growth Prospect Mapping for Technology, 2020
- 3.3 Market Dynamics
- 3.3.1 Market driver analysis
- 3.3.1.1 Increase in the incidence of coronavirus globally
- 3.3.1.1.1 North America
- 3.3.1.1.2 Europe
- 3.3.1.1.3 Asia Pacific
- 3.3.1.1.4 Latin America
- 3.3.1.1.5 Middle East and Africa
- 3.3.1.2 Increasing product approvals by regulatory agencies
- 3.3.1.3 Government initiatives toward mass testing
- 3.3.1.4 Paradigm shift toward POC testing
- 3.3.2 Market restraint analysis
- 3.3.2.1 Limited testing capacity
- 3.3.2.1 Low demand due to supply ratio of COVID-19 reagents
- 3.3.3 Market opportunity analysis
- 3.3.3.1 Potential emerging markets
- 3.3.3.2 Favorable reimbursement scenario
- 3.3.3.3 Increasing penetration of telehealth in the diagnosis of Covid-19
- 3.3.4 Market Challenge analysis
- 3.3.4.1 Challenges pertaining to COVID-19 testing in healthcare settings
- 3.4 COVID-19 Diagnostics Market - Porter's Analysis
- 3.4.1 Porter's Analysis
- 3.4.1.1 Competitive Rivalry - High
- 3.4.1.2 Threat of New Entrants - MoDERATE
- 3.4.1.3 Threat of Substitutes - Low
- 3.4.1.4 Bargaining Power of Suppliers - Moderate
- 3.4.1.5 Bargaining Power of Buyers - LoW
- 3.5 COVID-19 Diagnostics Market - SWOT Analysis
- 3.5.1 Political and Legal
- 3.5.1.1 Strengths
- 3.5.1.2 Weaknesses
- 3.5.1.3 Opportunities
- 3.5.1.4 Threats
- 3.5.2 Economic
- 3.5.2.1 Strengths
- 3.5.2.2 Weakness
- 3.5.2.3 Opportunity
- 3.5.2.4 Threat
- 3.5.3 Technological
- 3.5.3.1 Strengths
- 3.5.3.2 Weakness
- 3.5.3.3 Opportunity
- 3.5.3.4 Threat
- 3.6 COVID-19 Diagnostics: Company Position Analysis
- 3.7 COVID-19 Diagnostics: Healthcare Spending and Funding Scenario in Different Countries
- 3.7.1 U.S.
- 3.7.2 China
- 3.7.3 Brazil
- 3.7.4 Germany
- 3.7.5 Others
- 3.8 COVID-19 Diagnostics Market - Regulatory Framework
- 3.9 Effect on Swabs Market
- 3.9.1 Production shortage for viral transport media
- 3.9.2 Companies leading the viral transport media market
- 3.9.2.1 COPAN Diagnostics
- 3.9.2.2 PURITAN MEDICAL PRODUCTS
- 3.9.2.3 Becton, Dickinson and Company (BD)
- 3.9.2.4 Thermo Fisher Scientific
- 3.9.2.5 Other emerging companies
Chapter 4 Product & Service Business Analysis
- 4.1 COVID-19 Diagnostics Market: Product & Service Movement Analysis
- 4.2 Reagents & Kits
- 4.2.1 Global COVID-19 Diagnostics reagents & kits market, 2020 - 2030 (USD Million)
- 4.3 Instruments
- 4.3.1 Global COVID-19 Diagnostics instruments market, 2020 - 2030 (USD Million)
- 4.4 Services
- 4.4.1 Global COVID-19 Diagnostic services market, 2020 - 2030 (USD Million)
Chapter 5 Sample Type Business Analysis
- 5.1 COVID-19 Diagnostics Market: Sample Type Movement Analysis
- 5.2 Nasopharyngeal (NP) Swabs
- 5.2.1 Global COVID-19 Diagnostics nasopharyngeal swabs market, 2020 - 2030 (USD Million)
- 5.3 Oropharyngeal (OP) Swabs
- 5.3.1 Global COVID-19 Diagnostics oropharyngeal swabs market, 2020 - 2030 (USD Million)
- 5.4 Nasal Swabs
- 5.4.1 Global COVID-19 Diagnostics nasal swabs market, 2020 - 2030 (USD Million)
- 5.5 Blood
- 5.5.1 Global COVID-19 Diagnostics blood market, 2020 - 2030 (USD Million)
- 5.6 Others
- 5.6.1 Global COVID-19 Diagnostics other samples market, 2020 - 2030 (USD Million)
Chapter 6 Test Type Business Analysis
- 6.1 COVID-19 Diagnostics Market: Test Type Movement Analysis
- 6.2 Molecular (PCR) Testing
- 6.2.1 Global COVID-19 molecular (PCR) testing market, 2020 - 2030 (USD Million)
- 6.3 Antigen-based Testing
- 6.3.1 Global COVID-19 antigen-based testing market, 2020 - 2030 (USD Million)
- 6.4 Antibody (Serology) Testing
- 6.4.1 Global COVID-19 Diagnostics antibody (Serology) testing market, 2020 - 2030 (USD Million)
- 6.5 Others
- 6.5.1 Global COVID-19 other tests market, 2020 - 2030 (USD Million)
Chapter 7 Mode Business Analysis
- 7.1 COVID-19 Diagnostics Market: Mode Movement Analysis
- 7.2 Point-of-Care (PoC) Testing
- 7.2.1 Global COVID-19 Point-of-Care (PoC) testing market, 2020 - 2030 (USD Million)
- 7.3 Non Point-of-Care (Non-PoC) Testing
- 7.3.1 Global COVID-19 non-Point-of-Care (Non-PoC) testing market, 2020 - 2030 (USD Million)
Chapter 8 End-use Business Analysis
- 8.1 COVID-19 Diagnostics Market: End-use Movement Analysis
- 8.2 Laboratories
- 8.2.1 Global laboratories-based COVID-19 Diagnostics market, 2020 - 2030 (USD Million)
- 8.3 Hospitals
- 8.3.1 Global hospitals-based COVID-19 Diagnostics market, 2020 - 2030 (USD Million)
- 8.4 Diagnostic Centers and Clinics
- 8.4.1 Global diagnostic centers and clinics-based COVID-19 Diagnostics market, 2020 - 2030 (USD Million)
- 8.5 Others
- 8.5.1 Global other end-uses-based COVID-19 Diagnostics market, 2020 - 2030 (USD Million)
Chapter 9 Regional Business Analysis
- 9.1 Market: Regional Movement Analysis, 2020 &2030
- 9.2 North America
- 9.2.1 Market estimates and forecast, 2020 - 2030 (USD Million)
- 9.2.2 U.S.
- 9.2.2.1 Market estimates and forecast, by product & service, 2020 - 2030 (USD Million)
- 9.2.2.2 Market estimates and forecast, by sample type, 2020 - 2030 (USD Million)
- 9.2.2.3 Market estimates and forecast, by test type, 2020 - 2030 (USD Million)
- 9.2.2.4 Market estimates and forecast, by mode, 2020 - 2030 (USD Million)
- 9.2.2.5 Market estimates and forecast, by end-use, 2020 - 2030 (USD Million)
- 9.2.3 Canada
- 9.2.3.1 Market estimates and forecast, by product & service, 2020 - 2030 (USD Million)
- 9.2.3.2 Market estimates and forecast, by sample type, 2020 - 2030 (USD Million)
- 9.2.3.3 Market estimates and forecast, by test type, 2020 - 2030 (USD Million)
- 9.2.3.4 Market estimates and forecast, by mode, 2020 - 2030 (USD Million)
- 9.2.3.5 Market estimates and forecast, by end-use, 2020 - 2030 (USD Million)
- 9.3 Europe
- 9.3.1 Market estimates and forecast, 2020 - 2030 (USD Million)
- 9.3.2 Germany
- 9.3.2.1 Market estimates and forecast, by product & service, 2020 - 2030 (USD Million)
- 9.3.2.2 Market estimates and forecast, by sample type, 2020 - 2030 (USD Million)
- 9.3.2.3 Market estimates and forecast, by test type, 2020 - 2030 (USD Million)
- 9.3.2.4 Market estimates and forecast, by mode, 2020 - 2030 (USD Million)
- 9.3.2.5 Market estimates and forecast, by end-use, 2020 - 2030 (USD Million)
- 9.3.3 U.K.
- 9.3.3.1 Market estimates and forecast, by product & service, 2020 - 2030 (USD Million)
- 9.3.3.2 Market estimates and forecast, by sample type, 2020 - 2030 (USD Million)
- 9.3.3.3 Market estimates and forecast, by test type, 2020 - 2030 (USD Million)
- 9.3.3.4 Market estimates and forecast, by mode, 2020 - 2030 (USD Million)
- 9.3.3.5 Market estimates and forecast, by end-use, 2020 - 2030 (USD Million)
- 9.3.4 France
- 9.3.4.1 Market estimates and forecast, by product & service, 2020 - 2030 (USD Million)
- 9.3.4.2 Market estimates and forecast, by sample type, 2020 - 2030 (USD Million)
- 9.3.4.3 Market estimates and forecast, by test type, 2020 - 2030 (USD Million)
- 9.3.4.4 Market estimates and forecast, by mode, 2020 - 2030 (USD Million)
- 9.3.4.5 Market estimates and forecast, by end-use, 2020 - 2030 (USD Million)
- 9.3.5 Italy
- 9.3.5.1 Market estimates and forecast, by product & service, 2020 - 2030 (USD Million)
- 9.3.5.2 Market estimates and forecast, by sample type, 2020 - 2030 (USD Million)
- 9.3.5.3 Market estimates and forecast, by test type, 2020 - 2030 (USD Million)
- 9.3.5.4 Market estimates and forecast, by mode, 2020 - 2030 (USD Million)
- 9.3.5.5 Market estimates and forecast, by end-use, 2020 - 2030 (USD Million)
- 9.3.6 Spain
- 9.3.6.1 Market estimates and forecast, by product & service, 2020 - 2030 (USD Million)
- 9.3.6.2 Market estimates and forecast, by sample type, 2020 - 2030 (USD Million).
- 9.3.6.3 Market estimates and forecast, by test type, 2020 - 2030 (USD Million)
- 9.3.6.4 Market estimates and forecast, by mode, 2020 - 2030 (USD Million)
- 9.3.6.5 Market estimates and forecast, by end-use, 2020 - 2030 (USD Million)
- 9.3.7 Russia
- 9.3.7.1 Market estimates and forecast, by product & service, 2020 - 2030 (USD Million)
- 9.3.7.2 Market estimates and forecast, by sample type, 2020 - 2030 (USD Million)
- 9.3.7.3 Market estimates and forecast, by test type, 2020 - 2030 (USD Million)
- 9.3.7.4 Market estimates and forecast, by mode, 2020 - 2030 (USD Million)
- 9.3.7.5 Market estimates and forecast, by end-use, 2020 - 2030 (USD Million)
- 9.4 Asia Pacific
- 9.4.1 Market estimates and forecast, 2020 - 2030 (USD Million)
- 9.4.2 China
- 9.4.2.1 Market estimates and forecast, by product & service, 2020 - 2030 (USD Million)
- 9.4.2.2 Market estimates and forecast, by sample type, 2020 - 2030 (USD Million)
- 9.4.2.3 Market estimates and forecast, by test type, 2020 - 2030 (USD Million)
- 9.4.2.4 Market estimates and forecast, by mode, 2020 - 2030 (USD Million)
- 9.4.2.5 Market estimates and forecast, by end-use, 2020 - 2030 (USD Million)
- 9.4.3 India
- 9.4.3.1 Market estimates and forecast, by product & service, 2020 - 2030 (USD Million)
- 9.4.3.2 Market estimates and forecast, by sample type, 2020 - 2030 (USD Million)
- 9.4.3.3 Market estimates and forecast, by test type, 2020 - 2030 (USD Million)
- 9.4.3.4 Market estimates and forecast, by mode, 2020 - 2030 (USD Million)
- 9.4.3.5 Market estimates and forecast, by end-use, 2020 - 2030 (USD Million)
- 9.4.4 Japan
- 9.4.4.1 Market estimates and forecast, by product & service, 2020 - 2030 (USD Million)
- 9.4.4.2 Market estimates and forecast, by sample type, 2020 - 2030 (USD Million)
- 9.4.4.3 Market estimates and forecast, by test type, 2020 - 2030 (USD Million)
- 9.4.4.4 Market estimates and forecast, by mode, 2020 - 2030 (USD Million)
- 9.4.4.5 Market estimates and forecast, by end-use, 2020 - 2030 (USD Million)
- 9.4.5 South Korea
- 9.4.5.1 Market estimates and forecast, by product & service, 2020 - 2030 (USD Million)
- 9.4.5.2 Market estimates and forecast, by sample type, 2020 - 2030 (USD Million)
- 9.4.5.3 Market estimates and forecast, by test type, 2020 - 2030 (USD Million)
- 9.4.5.4 Market estimates and forecast, by mode, 2020 - 2030 (USD Million)
- 9.4.5.5 Market estimates and forecast, by end-use, 2020 - 2030 (USD Million)
- 9.4.6 Australia
- 9.4.6.1 Market estimates and forecast, by product & service, 2020 - 2030 (USD Million)
- 9.4.6.2 Market estimates and forecast, by sample type, 2020 - 2030 (USD Million)
- 9.4.6.3 Market estimates and forecast, by test type, 2020 - 2030 (USD Million)
- 9.4.6.4 Market estimates and forecast, by mode, 2020 - 2030 (USD Million)
- 9.4.6.5 Market estimates and forecast, by end-use, 2020 - 2030 (USD Million)
- 9.5 Latin America
- 9.5.1 Market estimates and forecast, 2020 - 2030 (USD Million)
- 9.5.2 Brazil
- 9.5.2.1 Market estimates and forecast, by product & service, 2020 - 2030 (USD Million)
- 9.5.2.2 Market estimates and forecast, by sample type, 2020 - 2030 (USD Million)
- 9.5.2.3 Market estimates and forecast, by test type, 2020 - 2030 (USD Million)
- 9.5.2.4 Market estimates and forecast, by mode, 2020 - 2030 (USD Million)
- 9.5.2.5 Market estimates and forecast, by end-use, 2020 - 2030 (USD Million)
- 9.5.3 Mexico
- 9.5.3.1 Market estimates and forecast, by product & service, 2020 - 2030 (USD Million)
- 9.5.3.2 Market estimates and forecast, by sample type, 2020 - 2030 (USD Million)
- 9.5.3.3 Market estimates and forecast, by test type, 2020 - 2030 (USD Million)
- 9.5.3.4 Market estimates and forecast, by mode, 2020 - 2030 (USD Million)
- 9.5.3.5 Market estimates and forecast, by end-use, 2020 - 2030 (USD Million)
- 9.6 Middle East and Africa (MEA)
- 9.6.1 Market estimates and forecast, 2020 - 2030 (USD Million)
- 9.6.2 South Africa
- 9.6.2.1 Market estimates and forecast, by product & service, 2020 - 2030 (USD Million)
- 9.6.2.2 Market estimates and forecast, by sample type, 2020 - 2030 (USD Million)
- 9.6.2.3 Market estimates and forecast, by test type, 2020 - 2030 (USD Million)
- 9.6.2.4 Market estimates and forecast, by mode, 2020 - 2030 (USD Million)
- 9.6.2.5 Market estimates and forecast, by end-use, 2020 - 2030 (USD Million)
- 9.6.3 Saudi Arabia
- 9.6.3.1 Market estimates and forecast, by product & service, 2020 - 2030 (USD Million)
- 9.6.3.2 Market estimates and forecast, by sample type, 2020 - 2030 (USD Million)
- 9.6.3.3 Market estimates and forecast, by test type, 2020 - 2030 (USD Million)
- 9.6.3.4 Market estimates and forecast, by mode, 2020 - 2030 (USD Million)
- 9.6.3.5 Market estimates and forecast, by end-use, 2020 - 2030 (USD Million)
Chapter 10 Competitive Landscape
- 10.1 Company/Competition Categorization (Key Innovators, Market leaders, Emerging Players)
- 10.2 Strategy Framework
- 10.3 Market Participation Categorization
- 10.4 Recent Developments & Impact Analysis, by Key Market Participants
- 10.5 Company Profiles
- 10.5.1 F. Hoffmann-La Roche AG
- 10.5.1.1 Company overview
- 10.5.1.2 Financial performance
- 10.5.1.3 Product benchmarking
- 10.5.1.4 Strategic initiatives
- 10.5.2 Thermo Fisher Scientific, Inc.
- 10.5.2.1 Company overview
- 10.5.2.2 Financial performance
- 10.5.2.3 Product benchmarking
- 10.5.2.4 Strategic initiatives
- 10.5.3 PerkinElmer, Inc.
- 10.5.3.1 Company overview
- 10.5.3.2 Financial performance
- 10.5.3.3 Product benchmarking
- 10.5.3.4 Strategic initiatives
- 10.5.4 1drop, Inc.
- 10.5.4.1 Company overview
- 10.5.4.2 Product benchmarking
- 10.5.4.3 Strategic initiatives
- 10.5.5 Veredus Laboratories
- 10.5.5.1 Company overview
- 10.5.5.2 Financial performance (Sekisui Chemical Co., Ltd.)
- 10.5.5.3 Product benchmarking
- 10.5.5.4 Strategic initiatives
- 10.5.6 ADT Biotech SdnBhd
- 10.5.6.1 Company overview
- 10.5.6.2 Product benchmarking
- 10.5.6.3 Strategic initiatives
- 10.5.7 altona Diagnostics GmbH
- 10.5.7.1 Company overview
- 10.5.7.2 Product benchmarking
- 10.5.7.3 Strategic initiatives
- 10.5.8 bioMerieux SA
- 10.5.8.1 Company overview
- 10.5.8.2 Financial performance
- 10.5.8.3 Product benchmarking
- 10.5.8.4 Strategic initiatives
- 10.5.9 Neuberg Diagnostics
- 10.5.9.1 Company overview
- 10.5.9.2 Product benchmarking
- 10.5.9.3 Strategic initiatives
- 10.5.10 Abbott Laboratories
- 10.5.10.1 Company overview
- 10.5.10.2 Financial performance
- 10.5.10.3 Product benchmarking
- 10.5.10.4 Strategic Initiatives
- 10.5.11 Luminex Corporation
- 10.5.11.1 Company overview
- 10.5.11.2 Financial performance
- 10.5.11.3 Product benchmarking
- 10.5.11.4 Strategic Initiatives
- 10.5.12 Laboratory Corporation of America Holdings
- 10.5.12.1 Company overview
- 10.5.12.2 Financial performance
- 10.5.12.3 Product benchmarking
- 10.5.12.4 Strategic Initiatives
- 10.5.13 Hologic Inc.
- 10.5.13.1 Company overview
- 10.5.13.2 Financial performance
- 10.5.13.3 Product benchmarking
- 10.5.13.4 Strategic Initiatives
- 10.5.14 Quest Diagnostics, Inc.
- 10.5.14.1 Company overview
- 10.5.14.2 Financial performance
- 10.5.14.3 Product benchmarking
- 10.5.14.4 Strategic Initiatives
- 10.5.15 Quidel Corporation
- 10.5.15.1 Company overview
- 10.5.15.2 Financial performance
- 10.5.15.3 Product benchmarking
- 10.5.15.4 Strategic Initiatives
- 10.5.16 ALDATU BIOSCIENCES
- 10.5.16.1 Company overview
- 10.5.16.2 Product benchmarking
- 10.5.16.3 Strategic Initiatives
- 10.5.17 Mylab Discovery Solutions Pvt. Ltd.
- 10.5.17.1 Company overview
- 10.5.17.2 Product benchmarking
- 10.5.17.3 Strategic Initiatives
- 10.5.18 Danaher Corporation
- 10.5.18.1 Company overview
- 10.5.18.2 Financial performance
- 10.5.19 Cepheid
- 10.5.19.1 Company overview
- 10.5.19.2 Product benchmarking (Cepheid)
- 10.5.19.3 Strategic Initiatives
- 10.5.20 Beckman Coulter, Inc.
- 10.5.20.1. Company overview
- 10.5.20.2 Product benchmarking (Beckman Coulter)
- 10.5.20.3 Strategic Initiatives